Patents Assigned to Merck
  • Tri-aryl-substituted-ethane PDE4 inhibitors
    Patent number: 6841564
    Abstract: Novel ethanes substituted with i) a phenyl, ii) a thiazole, and iii) a pyridyl moiety are PDE4 inhibitors.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck Frosst Canada & Co.
    Inventors: Richard Freisen, Yves Ducharme, Bernard Cote, Marc Blouin, Evelyn Martins, Daniel Guay, Pierre Hamel, Mario Girard, Richard Frenette, Sebastien Laliberte
  • Mono-, oligo- and polydithienopyridine
    Patent number: 6841677
    Abstract: The invention relates to new conjugated mono-, oligo- and polydithienopyridines, their use as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaics, sensors and electrophotographic recording devices, and to a field effect transistor as a component of integrated circuitry, as a thin fim transistor in flat panel display applications or for RFID tags, or a semiconducting component in organic light-emitting diode applications, comprising the new mono-, oligo and polydithienopyridines.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck Patent Gesellschaft Mit Beschraenkter
    Inventors: Martin Heeney, Steven Tierney, Marcus Thompson, Mark Giles, Louise Farrand, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • N-(indolcarbonyl-)piperazine derivatives
    Patent number: 6838461
    Abstract: Compounds of the formula I in which R1, R2, R4 and R5 have the meanings indicated in claim 1, are potent 5-HT2A antagonists and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkingson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, nervous anorexia, premenstrual syndrome and/or for positively affecting compulsive behavior (obsessive-compulsive disorder, OCD).
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: January 4, 2005
    Assignee: Merck Patent GmbH
    Inventors: Henning Boettcher, Christoph Seyfried
  • Radioligand and binding assay
    Patent number: 6838291
    Abstract: The present invention is directed to the radioligand compound, [35S]-radiolabeled (+)-N-[1?-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydoxyspiro[2H-1-benzopyran-2,4?-piperidin]-6-yl]methanesulfonamide. Also within the scope of this invention is a method for identifying compounds that bind to the IKr channel, and may have antiarrhythmic activity.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: January 4, 2005
    Assignee: Merck & Co., Inc.
    Inventors: John W. Butcher, David A. Claremon, Thomas M. Connolly, Jerzy Karczewski, Kenneth S. Koblan, Matthew J. Kostura, Nigel J. Liverton, Dennis C. Dean, David G. Melillo
  • Estrogen receptor modulators
    Patent number: 6838584
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: January 4, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Timothy Allen Blizzard, Milton Lloyd Hammond, Jerry Dwain Morgan, Ralph Troy Mosley
  • Isoforms of mouse serotonin 5-HT2c receptor
    Patent number: 6835548
    Abstract: The invention includes mouse serotonin 5-HT2c receptor isoforms having amino acid replacements at one or more positions of the natural mouse serotonin 5-HT2c receptor polypeptide sequence, specifically at one or more of positions 157, 159 and 161. The polypeptides are useful for identifying ligands which bind with the serotonin 5-HT2c receptor and modulators of the serotonin 5-HT2c, and for identifying drugs with affinity for 5-HT2 receptors which are used to treat schizophrenia, Parkinsonism, and anxiety disorders.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: December 28, 2004
    Assignee: Merck & Company, Inc.
    Inventors: Tong M. Fong, Jie Liu, Leonardus H.T. Van Der Ploeg
  • Iodohydroxylation of olefins
    Patent number: 6835860
    Abstract: Iodohydroxylated olefins can be prepared by treating an olefin with an aqueous solution of an iodine monohalide selected from iodine monochloride and iodine monobromide.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: December 28, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Yongkui Sun, Thorsten Rosner
  • Cathepsin cysteine protease inhibitors
    Patent number: 6835727
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: December 28, 2004
    Assignees: Merck Frosst Canada & Co., Banyu Pharmaceutical Co., Ltd., Axys Pharmaceuticals, Inc.
    Inventors: Osamu Okamoto, Jean-Pierre Falgueyret, Renata Marcella Oballa, Petpiboon Prasit, Robert Rydzewski
  • Process for making substituted 8-arylquinolinium benzenesulfonate
    Patent number: 6835837
    Abstract: A substituted 8-aryl quinoline and its benzenesulfonic acid salt is synthesized.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: December 28, 2004
    Assignee: Merck & Co. Inc.
    Inventors: Richard Desmond, David A. Conlon, Antoinette Drahus, Guo-Jie Ho, Brenda Pipik, Carl Leblond, Anant Vailaya
  • Method and system for the processing of order transactions
    Publication number: 20040254849
    Abstract: The present invention relates to a system for the processing of order transactions with a data memory, a recording device which is provided to record order data from a purchaser, a processing unit for the storage of recorded order data in the data memory. Furthermore, the present invention relates to a method for the processing of order transactions between a supplier and a purchaser, which has the steps of the recording of order data which consist of individual data fields, and transmission by the purchaser to the supplier, the creation of a file which contains data fields which represent at least some of the order data and the transmission of the file to the purchaser.
    Type: Application
    Filed: July 25, 2003
    Publication date: December 16, 2004
    Applicant: Merck Patent GmbH
    Inventor: Manuel Brocke-Benz
  • Liquid-crystalline medium
    Patent number: 6827990
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it comprises one or more compounds of the formula I in which R1, L1 and L2 are as defined in claim 1.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: December 7, 2004
    Assignee: Merck Patent GmbH
    Inventors: Michael Heckmeier, Brigitte Schuler, Izumi Saito, Volker Reiffenrath, Georg Luessem, Christian Hock
  • Liquid crystalline medium
    Patent number: 6827989
    Abstract: The invention relates to a liquid-crystalline medium with positive dielectric anisotropy and high optical anisotropy, characterized in that it contains one or more biphenyl derivatives comprising a terminal alkenyl group, and its use in electrooptical displays and projection systems, in particular reflective displays and displays based on a birefringence effect, such as OCB displays.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: December 7, 2004
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Volker Reiffenrath
  • Triazolo-pyridazine derivatives as ligands for GABA receptors
    Patent number: 6828322
    Abstract: A class of substituted 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing a fluoro-substituted phenyl ring at the 3-position and a heteroaryl-methoxy moiety at the 6-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: December 7, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: William Robert Carling, Jose Luis Castro Pineiro, Ian James Collins, Alexander Richard Guiblin, Timothy Harrison, Andrew Madin, Kevin William Moore, Michael Geoffrey Russell, Gayle Scott, Leslie Joseph Street
  • Mono-, Oligo- and poly-difluorovinyl-(hetero)arylenes, their synthesis and their use as charge transport materials
    Patent number: 6824706
    Abstract: The invention relates to new mono-, oligo- and poly-difluorovinyl(hetero)arylenes comprising one or more identical or different recurring units of formula I wherein D, D′, Ar, a and b have the meanings as defined in herein. Furthermore the inventions relates to their synthesis, their use as semiconductors or charge transport materials and their different applications.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: November 30, 2004
    Assignee: Merck Patent Gesellschaft mit beschrank Haftung
    Inventors: Martin Heeney, Louise Farrand, Mark Giles, Marcus Thompson, Steven Tierney, Maxim Shkunov, David Sparrowe, Iain McCulloch
  • Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
    Patent number: 6825322
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. The NMDA receptor subunits of the invention comprise components of NMDA receptors that have cation-selective channels and bind glutamate and NMDA. In one aspect of the invention, the nucleic acids encode NMDAR1 and NMDAR2 subunits of human NMDA receptors. In a preferred embodiment, the invention nucleic acids encode NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C and NMDAR2D subunits of human NMDA receptors. In addition to being useful for the production of NMDA receptor subunit proteins, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: November 30, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Lorrie P. Daggett, Chin-Chun Lu
  • Liquid-crystalline medium and liquid-crystal display
    Patent number: 6821580
    Abstract: The invention relates to a liquid-crystalline medium of positive dielectric anisotropy, characterized in that it comprises in each case one or more compounds of the general formulae I, II and IV in which the parameters are as defined in the text, and to the use thereof as a constituent of a multibottle system and in electro-optical displays, and to multibottle systems of this type and displays which contain this medium.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: November 23, 2004
    Assignee: Merck Patent GmbH
    Inventors: Kazuaki Tarumi, Brigitte Schuler, Sabine Schoen
  • Process for the preparation of cyclo(Asp-DPhe-NMeVal-Arg-Gly)
    Patent number: 6822074
    Abstract: Process for the preparation of the cyclic pentapeptide cyclo(Arg-Gly-Asp-DPhe-NMeVal) by cyclization of a linear pentapeptide selected from the group consisting of H-Arg(Pbf)-Gly-Asp(OBzl)-DPhe-NMeVal-OH, H-Gly-Asp(OBzl)-DPhe-NMeVal-Arg(Pbf)-OH, H-Asp(OBzl)-DPhe-NMeVal-Arg(Pbf)-Gly-OH, H-DPhe-NMeVal-Arg(Pbf)-Gly-Asp(OBzl)-OH or H-NMeVal-Arg(Pbf)-Gly-Asp (OBzl)-DPhe-OH, subsequent protective group removal and, if appropriate, further conversion into its physiologically acceptable salts.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: November 23, 2004
    Assignee: Merck Patent GmbH
    Inventors: Alfred Jonczyk, Markus Arnold
  • Liquid-crystalline mixtures
    Patent number: 6821582
    Abstract: A liquid-crystalline mixture that contains one or more compounds of each of the formulae IA, IB and IC and to the use thereof in TN, STN and IPS displays.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: November 23, 2004
    Assignee: Merck Patent GmbH
    Inventors: Harald Hirschmann, Volker Reiffenrath, Marcus Reuter, Sabine Schoen, Sven Schüpfer, Clarissa Weller
  • Method and device for the online analysis of solvent mixtures
    Patent number: 6820013
    Abstract: The invention relates to a method and an apparatus for the on-line analysis of liquid substance mixtures by means of NIRS. For evaluation by spectral data comparison, merely the binary mixtures of the possible components in quantitative graduations are used as calibration spectra. In order to accelerate the evaluation, all data points of a spectrum are summated, and each spectrum is characterized by only one characteristic number.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: November 16, 2004
    Assignee: Merck Patent GmbH
    Inventors: Hans Frickel, Hanshelmut Itzel, Joachim Born
  • Acylated piperidine derivatives as melanocortin-4 receptor agonists
    Patent number: 6818658
    Abstract: Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: November 16, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Feroze Ujjainwalla, Lin Chu, Mark T. Goulet, Bonnie Louridas, Matthew J. Wyvratt, Daniel Warner